Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Amivantamab Plus Chemotherapy with and Without Lazertinib in EGFR-mutant Advanced NSCLC after Disease Progression on Osimertinib: Primary Results from the Phase III MARIPOSA-2 Study.

A. Passaro,J. Wang, Y. Wang,S. -H. Lee,B. Melosky,J. -Y. Shih,K. Azuma,O. Juan-Vidal,M. Cobo,E. Felip,N. Girard,A. B. Cortot,R. Califano,F. Cappuzzo,S. Owen,S. Popat,J. -l. Tan, J. Salinas,P. Tomasini,R. D. Gentzler,W. N. William,K. L. Reckamp, T. Takahashi, S. Ganguly,D. M. Kowalski,A. Bearz,M. MacKean, P. Barala,A. B. Bourla, A. Girvin, J. Greger,D. Millington, M. Withelder,J. Xie,T. Sun, S. Shah,B. Diorio,R. E. Knoblauch,J. M. Bauml, R. G. Campelo,B. C. Cho

ANNALS OF ONCOLOGY（2024）

Cited 93|Views87
Key words
amivantamab,lazertinib,EGFR-mutated,NSCLC,post-osimertinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined